John-Michel Huss

BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun.

Innovative Medicines Canada manufactures medical and toilet products. The company was founded on April 23, 1914 and is headquartered in Ottawa, Canada.

ADVANZ PHARMA Corp. Ltd. is a pharmaceutical company engages in the provision of branded and unbranded products. The firm specializes in anti-Infectives and endocrinology therapy areas. It operates through the following segments: Advanz Pharma International; Advanz Pharma North America; and Corporate. The Advanz Pharma International segment include portfolio of branded and generic products that are sold to wholesalers, hospitals, and pharmacies. The Advanz Pharma North America segment comprises branded products and authorized generic contracts that focuses primarily on the U.S. pharmaceutical market. The Corporate segment represents the centralized costs. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in St. Helier, the United Kingdom.

H&P Labs, Inc. operates as a biotechnology firm. It develops drugs to fight infectious viral diseases for public health and biodefense missions. The company was founded by John Michel T. Huss on June 7, 2013 and is headquartered in Westmount, Canada.

Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada.